Blood Testing for Triple-Negative Breast Cancer Treatment
CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 422 (estimated)
- Sponsor
- Personalis Inc. · Industry
This trial is looking for patients with early-stage triple-negative breast cancer who are starting treatment with chemotherapy. Participants will provide blood samples to help understand the effectiveness of a new testing method during their treatment.
You may be able to join if
- I have been diagnosed with triple-negative breast cancer.
- I have early-stage breast cancer and will start chemotherapy soon.
- I am at least 18 years old.
- I am willing to provide blood samples before and during treatment.
- I am willing to sign a consent form for the trial.
- I have available biopsy tissue.
You may not be able to join if
- I have stage IV breast cancer.
- I am currently being treated for another type of cancer.
- I have had another primary cancer in the last 5 years.
- I have had a bone marrow or organ transplant.
- I have had a blood transfusion in the last two weeks.
- I have already started other chemotherapy for my breast cancer.
- I am pregnant.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityA prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Loading trial locations…